Abstract 834P
Background
Marginal zone lymphoma (MZL) is a relatively common group of inert B-cell non-Hodgkin’s lymphoma (B-NHL) originating from peripheral memory lymphocytes. Some patients cannot achieve complete remission or relapse quickly after standard first-line treatment. Studies have shown that the NF-KB signal pathway in MZL is in an abnormally activated state, while bortezomib is a proteasome inhibitor targeting the NF-KB pathway. This multicenter phase II clinical study evaluated the efficacy and safety of VR-CAP regimen in the first-line treatment of MZL, and explored the best beneficiaries of VR-CAP regimen (rituximab, cyclophosphamide, epirubicin, bortezomib and prednisone).
Methods
The patient received 6 cycles of VR-CAP first-line treatment. Each cycle lasts for 3 weeks, and rituximab (375 mg/m2) is given intravenously on the 0th day, cyclophosphamide (750 mg/m2) and epirubicin (70 mg/m2) are given intravenously on the 1st day, bortezomib (1.3 mg/m2) is given subcutaneously on the 1st and 4th days, and prednisone (100 mg) is given orally on the 1st to 5th days. The primary end point was 2-year progression-free survival (PFS), and the secondary end point was objective response rate (ORR), including complete response (CR) and partial response (PR); Total survival (OS) and security.
Results
At present, 23 patients were enrolled, the median age was 55 years (25-74 years). By February 2023, 15 patients had completed all six courses of treatment; 6 patients completed 4 courses of treatment; Two patients stopped treatment by themselves, and 22 patients could evaluate the curative effect. Sixteen patients (72.7%) and five patients (22.7%) achieved CR/CRu and PR respectively. PFS and OS were 82.2% and 82.0% respectively in two years. Among the 13 patients who have completed all the treatment, the common therapeutic adverse events are anemia (73.9%), gastrointestinal reaction (52.2%), thrombocytopenia (30.4%), pulmonary infection (21.7%), neurotoxicity (8.7%), rituximab-related rash (8.7%).
Conclusions
VR-CAP first-line treatment of lymphoma in the marginal region has a good effect, the objective response rate (ORR) is 95.5%, and the patient is well tolerated. All adverse events are mainly 1-2 grades.
Clinical trial identification
NCT04433156.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18